SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Report abuse about a comment

@kushal

Thanks Kushal - glad to hear you enjoyed the article.

Posted by Nick Taylor
29 November 2010 | 08h49

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Nose-to-brain delivery possible but challenges remain

Spotlight

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

GMP failures at an aseptic plant owned by SCM Pharma are part of a wider industry trend...

Boehringer aims to cut German costs 15% as H1 sales fall

Boehringer Ingelheim aims to cut German costs 15% as revenues drop

German jobs are safe despite a programme that will cut the cost of operations by 15%, Boehringer...

WHO: Data from use of unapproved Ebola drugs should be shared

WHO: Data from use of unapproved Ebola drugs should be shared

Efficacy and safety data from use of unapproved Ebola virus treatments should be shared according to an...

THC may reduce tumor size? mouse study investigates

THC may reduce tumor size? mouse study investigates

A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in...

India’s CDSCO outlines procedures for state manufacturer inspections

India’s CDSCO outlines procedures for state inspections of manufacturers

In order to ensure uniformity on the state and federal levels, India’s CDSCO (Central Drugs Standard Control...

Roche re-enters RNAi space with $250m Santaris acquisition

Roche re-enters gene silencing space with $250m LNA acquisition

Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its...

Key Industry Events

 

Access all events listing

Our events, Events from partners...